Drugs / NXP900
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07315113 | Dec 2025 → Dec 2026 expected | lung cancer | Nuvectis Pharma, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05873686 | Oct 2023 → Mar 2027 expected | kidney cancer, lung adenocarcinoma, mesothelioma, non-small cell squamous lung carcinoma | Nuvectis Pharma, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 11
| Date | Issuer | Release |
|---|---|---|
| 2026-03-31 | Nuvectis Pharma, Inc. | Results Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting nuvectis.com ↗
NXP900, a Phase 1b, first-in-class YES1/SRC inhibitor demonstrates potent synergy with KRAS inhibitors in KRASi sensitive and resistant NSCLC models |
| 2025-10-27 | Nuvectis Pharma, Inc. | Results Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics nuvectis.com ↗
The results from the Phase1a dose escalation and clinical drug-drug interaction studies are important building blocks in NXP900's clinical development journey to hopefully become a best-in-class SRC/YES1 inhibitor with broad clinical applications. |
| 2025-07-08 | Nuvectis Pharma, Inc. | Results Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies nuvectis.com ↗
As per the International Council for Harmonization ("ICH") M12, topline results from the NXP900 DDI clinical study classify NXP900 as a weak inhibitor of CYP3A; these results support the combination strategy of NXP900 with EGFR/ALK Inhibitors in NSCLC and potentially additional combinations. |
| 2025-04-29 | Nuvectis Pharma, Inc. | Results Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting nuvectis.com ↗
Phase 1a dose-escalation study data update: treatment with NXP900 resulted in exposure levels leading to robust pharmacodynamic responses across a range of tolerated doses |
| 2025-03-04 | Nuvectis Pharma, Inc. | Results Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC nuvectis.com ↗ |
| 2024-04-08 | Nuvectis Pharma, Inc. | Results Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines nuvectis.com ↗
In addition, NXP900 demonstrated potent, single agent, antiproliferative activity in anaplastic lymphoma kinase (ALK)-resistant NSCLC cells and synergistic effects in combination with alectinib in alectinib sensitive cells. |
| 2023-05-15 | Nuvectis Pharma, Inc. | Regulatory Nuvectis Pharma Announces FDA Clearance of NXP900 IND nuvectis.com ↗
Fort Lee, NJ, May 15, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the U.S. Food and Drug Administration ("FDA") cleared the Company's Investigational New Drug Application ("IND") for NXP900, which includes the Phase 1 clinical trial protocol. |
| 2022-10-18 | Nuvectis Pharma, Inc. | Results Nuvectis Phrama Announces Two Upcoming Poster Presentations at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics nuvectis.com ↗
The posters that will be presented at the 2022 ENA describe the preclinical validation of biomarkers supporting the clinical development of NXP800, and identify additional target tumors and potential clinical development opportunities for NXP900, further differentiating it from non-selective SRC/YES1 inhibitors. |
| 2022-06-13 | Nuvectis Pharma, Inc. | Results Nuvectis Pharma Announces Positive Data for NXP900 in a Preclinical Model of Group 4 Medulloblastoma, A Type of Brain Cancer That Affects Predominantly Pediatric Patients nuvectis.com ↗
Treatment with NXP900 resulted in substantial tumor growth inhibition and a survival benefit versus the control. |
| 2022-04-13 | Nuvectis Pharma, Inc. | Results Nuvectis Pharma Recaps Poster Presentation Highlights for NXP900 at the 2022 American Association for Cancer Research (AACR) Conference nuvectis.com ↗ |
| 2022-02-22 | Nuvectis Pharma, Inc. | Results Nuvectis Announces Positive Data for NXP900 in Triple Negative Breast Cancer Preclinical Models with an Integrin-Linked Kinase (ILK) Loss nuvectis.com ↗
Publication highlights potent activity of NXP900, a differentiated inhibitor of the SRC/YES1 Kinases |
All press releases naming this drug 20 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NXP900 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07315113 ↗ |
| Known as | DERIVATIVE 11A | ChEMBL registry synonym — accepted as the source's own label CHEMBL3824089 ↗ |
| Known as | ECF506 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3824089 ↗ |
| Action | Inhibit | “NXP900 is an orally administered SRC/YES1 kinase inhibitor” NCT05873686 ↗ |
| Modality | Small molecule | — CHEMBL3824089 ↗ |
| Route | Oral | “NXP900 is an orally administered SRC/YES1 kinase inhibitor” NCT05873686 ↗ |
| Target | SRC | “NXP900 is an orally administered SRC/YES1 kinase inhibitor” NCT05873686 ↗ |
| Target | YES1 | “NXP900 is an orally administered SRC/YES1 kinase inhibitor” NCT05873686 ↗ |